semaglutide news today october 2025 Pentagon Drops Coverage of GLP-1 Weight Loss Meds for Medicare-Eligible Retirees Is India about to make

Some research suggests that semaglutide may indirectly influence dopamine levels by affecting the brains reward system

(Note The ATTAIN-1 trial is investigating the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.) Orforglipron Orforglipron is an orally bioavailable, non-peptide agonist of the GLP-1 receptor

Faster Market Entry Indian manufacturers provide ready dossiers, stability data, and export documentation, allowing distributors to register and launch products quickly

Vanessa Lee of The Things We Do explains why more people are starting cosmetic treatments earlier and how subtle procedures done sooner may reduce the need for more invasive interventions later